Peer review reports
From: Combination of gemcitabine, nab-paclitaxel, and S-1(GAS) as the first-line treatment for patients with locally advanced or advanced pancreatic ductal adenocarcinoma: study protocol for an open-label, single-arm phase I study
Original Submission |
28 Mar 2021 |
Submitted |
Original manuscript
|
6 Apr 2021 |
Author responded |
Author comments - Chen Chang
|
Resubmission - Version 2 |
6 Apr 2021 |
Submitted |
Manuscript version 2
|
26 Apr 2021 |
Author responded |
Author comments - Chen Chang
|
Resubmission - Version 3 |
26 Apr 2021 |
Submitted |
Manuscript version 3
|
Publishing |
29 Apr 2021 |
Editorially accepted |
|
13 May 2021 |
Article published |
10.1186/s12885-021-08275-9
|
Learn about peer review